Go Freelance Jobs

Cancer Treatment Centers Of America Announce Details Of New Partnership

The national organization Cancer Treatment Centers of America, Inc. (CTCA) has teamed up with two other companies in the healthcare industry in order to improve cancer treatment at their hospitals around the United States. The new platform, which they have named Clinical Pathways, was officially launched in February 2017 and is already swiftly making positive results for cancer patients a reality.
The partnership is between Cancer Treatment Centers of America, Allscripts, and NantHealth. Allscripts contributed their electronic health records database to the Clinical Pathways project while NantHealth provider their clinical decision support platform. The end goal of Clinical Pathways is to quickly provide physicians with each patient’s treatment options which are specialized for their individual situation. This will help eliminate a lot of the guesswork that physicians have had to engage with in the past. Among other things, Clinical Pathways also provides the Oncologist with information such as adverse drug reactions, response rates, and current guidelines.
It was in 1988 that CTCA was founded by Richard Stephenson. It has treated hundreds of thousands of cancer patients since that time. The first hospital that was part of CTCA was the Midwestern Regional Medical Center in Zion, Illinois. There are now four other hospitals that are part of the network spread across the continental United States.
At each of the hospital that makes up CTCA, each patient is given individualized attention by the doctors and nurses. In addition to providing treatment for their medical condition, they also help patients cope with the adverse effects of their treatment procedures. This can include fatigue, nausea, pain, and anxiety among other effects. CTCA uses a conventional approach to cancer care which can include surgery, chemotherapy, and radiation in order to irradicate cancer from the patient’s body.

More information on CTCA can be found on Twitter.

Leave a Reply